ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
(1) The phase IIa proof-of-concept findings from ViiV Healthcare's innovative early pipeline of medicines show the antiviral activity, safety and tolerability of GSK'254 and support its continued study in phase IIb ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive data from its phase IIa proof-of-concept study of the investigational maturation inhibitor GSK3640254 (GSK'254). The study showed the antiviral activity of GSK'254, establishing a relationship between dose and antiviral response, with t...